Hormonal
Treatment with GLP-1 receptor agonists (GLP-1 RAs) or dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) significantly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality in overweight or obese adults without diabetes compared to placebo.
If you are overweight or obese and do not have diabetes, treatment with GLP-1 or GIP/GLP-1 receptor agonists (such as semaglutide, liraglutide, or tirzepatide) has been shown in large studies to significantly lower your risk of major heart events (like heart attack and stroke) and death from any cause compared to taking a placebo. This benefit exists independently of diabetes status.
GLP-1 or GIP/GLP-1 RAs reduced MACE (odds ratio (OR): 0.79; 95% confidence interval (CI): 0.71–0.89; p < 0.01; I2 = 0) and all-cause mortality (OR: 0.80; 95% CI: 0.70–0.92; p < 0.01; I2 = 0)... compared to placebo.
Why this rating
Based on a systematic review and meta-analysis of 16 randomized-controlled trials (RCTs) involving 28,168 participants with low heterogeneity.
Source
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
Maria‐Ioanna Stefanou et al. · Therapeutic Advances in Neurological Disorders · 2024
DOI 10.1177/17562864241281903
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →